Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
MDVerse logo — company profile

MDVerse

Founded 2022 United States Fremont, United States 2 employees Seed Total: $750.00K Biotechnology, Health and Wellness +1

General Information

Company Name MDVerse
Founded Year 2022
Location United States Fremont, United States
Employees 2
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Seed
Business Model B2B, Platform, SaaS
Revenue Model Subscription, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with MDVerse. To contact MDVerse, visit mdverse.io.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MDVerse compare?

A PDF of MDVerse and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MDVerse soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MDVerse

MDVerse, founded in 2022, operates at the intersection of Biotechnology, Health and Wellness, and Pharmaceutical industries, aiming to revolutionize these sectors through innovation and cutting-edge solutions. Based in the United States, it positions itself as a burgeoning player in the health tech ecosystem.

The company secured a $750.00K Seed Round investment on 01 January 2023, a significant milestone that was led by the PGV Fund 1. This capital injection indicates strong investor confidence in MDVerse's potential to deliver impactful advances in its field.

MDVerse's strategic focus and early traction make it an enticing prospect for further investment, with opportunities for growth in a market that consistently demands innovation. It stands poised at the forefront of transformative solutions in healthcare, leveraging its foundation in biotechnology and wellness to address critical needs in a rapidly evolving landscape.

Business keywords: virtual reality, augmented reality, immersive technologies, gaming, technology, startup, investment, innovation

Services & Products

Personalized Precision Therapies Development
Software Analytics Integration with Therapeutics
Supporting Clinical Trials
Bench-to-Bedside Transition

Target Customers

Pharmaceutical Companies Biotech Firms Clinical Researchers Healthcare Providers Academic Institutions

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $750.00K 1
PGV Fund 1
PGV Fund 1
01 Jan 2023

MDVerse Alternatives & Competitors

View All Alternatives
MDVerse vs
Caribou Biosciences
Caribou Biosciences United States

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating hu...

IPO
128 employees
Biotechnology, Health Care
MDVerse vs
Neogene Therapeutics
Neogene Therapeutics The Netherlands

Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid ca...

Acquired
45 employees
Biotechnology, Health Care
MDVerse vs
BDD
BDD United Kingdom

Redefining Early Stage Development

Venture round
54 employees
Biopharma, Biotechnology
View all alternatives

FAQ About MDVerse

MDVerse
MDVerse was founded in 2022.
MDVerse is headquartered in Fremont, United States.
MDVerse operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on virtual reality, augmented reality, immersive technologies and gaming. Its customers include Pharmaceutical Companies, Biotech Firms and Clinical Researchers.
MDVerse has a B2B, Platform and SaaS business model. Its revenue comes from Subscription, Licensing and Service Fee.
MDVerse has approximately 2 employees.
MDVerse has completed 1 funding round, raising a total of $750.00K. The latest funding stage is Seed.
MDVerse offers: Personalized Precision Therapies Development, Software Analytics Integration with Therapeutics, Supporting Clinical Trials, Bench-to-Bedside Transition.
Top alternatives and competitors to MDVerse include Caribou Biosciences, Neogene Therapeutics, BDD, Intellia Therapeutics, Inc., Recursion. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MDVerse and Caribou Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MDVerse, https://bouncewatch.com/company/mdverse, updated 2 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes